REDWOOD CITY, Calif., Aug. 20, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that Dr. Pamela Palmer, Chief Medical Officer, will be presenting at the 2018 Military Health System Research Symposium (MHSRS) on August 20, 2018. The presentation is entitled "Gender Differences in Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Treatment of Moderate-to-Severe Acute Pain."
Details of the event are as follows:
Date: Monday, August 20, 2018
Location: Gaylord Palms Convention Center, Kissimmee, FL
Presentation Time: 4:15pm ET
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has two product candidates in the United States including DSUVIA™ (sufentanil sublingual tablet, 30 mcg), with a proposed indication for the treatment of moderate-to-severe acute pain in medically supervised settings, and Zalviso® (sufentanil sublingual tablet system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in hospitalized patients. DZUVEO™, as DSUVIA is known in Europe, and Zalviso are both approved products in Europe.
For additional information about AcelRx, please visit www.acelrx.com.
SOURCE AcelRx Pharmaceuticals, Inc.